Obagi Medical Products Launches Two New Systems to Optimize Results of Non-Surgical and Surgical Facial Aesthetic Procedures

Business Wire, August 22, 2007

LONG BEACH, Calif. -- Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, today introduced two new Obagi[R] Condition & Enhance Systems. One is designed specifically for use with non-surgical procedures while the other has been developed for use with surgical procedures. Both Systems are based on Obagi's Penetrating Therapeutics[TM] technologies, and are designed to complement facial procedures and improve overall aesthetic results.

In addition to improving the overall skin appearance resulting from cosmetic procedures (including Botox[R], fillers, microdermabrasion, laser procedures and chemical peels):

The Obagi Condition & Enhance System for Use with Non-Surgical Procedures:

* Evens skin tone and reduces hyperpigmentation

* Assists in achieving a greater overall improved appearance of the face

* Promotes overall skin health

The Obagi Condition & Enhance System for Use with Surgical Procedures:

* Optimizes penetration and prepares the skin for the procedure

* Assists in reducing post-inflammatory hyperpigmentation (PIH)

* Evens mottled hyperpigmentation (discoloration)

Rick Kozloski, Vice President Marketing & Dermatology of Obagi Medical Products, stated, "Americans spent $12 billion on plastic surgical procedures last year. Obagi has gathered compelling clinical data to support the benefits of the use of these new systems in conjunction with both non-surgical and surgical facial aesthetic procedures. We believe that physicians can help their patients achieve greater satisfaction from these procedures by using the Obagi Condition & Enhance System."

The System for non-surgical procedures contains six products including Foaming Gel, Toner, Clear, Exfoderm Forte, Blender and Healthy Sunscreen SPF 35. The System for surgical procedures includes Gentle Cleanser, Toner, Exfoderm, Blender, Healthy Sunscreen SPF 35 and Physical UV Block. Each System retails for $408 and the travel size System retails for $199. The Obagi Condition & Enhance Systems are available at dermatologists' and plastic surgeons' offices nationwide starting today. To locate a physician who carries the Obagi Condition & Enhance System, log onto www.obagi.com.

About Obagi Medical Products, Inc.

Obagi Medical Products develops and commercializes skin health products for the dermatology, plastic surgery, and related aesthetic markets. Using its Penetrating Therapeutics[TM] technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including chloasma, melasma, senile lentigines, acne vulgaris and sun damage. The history of Obagi's skin care product introductions is as follows: Obagi Nu-Derm, 1988; Obagi-C Rx (the first and only prescription-strength vitamin C and hydroquinone system), 2004; Obagi Professional-C (a line of highly stable vitamin C serums), 2005; Obagi Nu-Derm, 2006; Obagi ELASTIderm eye skin care and Obagi CLENZIderm M.D. acne therapeutic systems 2007; a formulation of CLENZIderm for normal to dry skin, July 2007; and Obagi Condition and Enhance Systems for use with non-surgical and surgical cosmetic procedures to enhance patient outcomes and satisfaction; August 2007. Obagi's products are only available through physicians. Visit www.obagi.com for information.

Forward Looking Statements

There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should," "potential," "anticipates," "plans," or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the intense competition our products face and will face in the future, the level of market acceptance of our products, the possibility that our products could be rendered obsolete by technological or medical advances, the possibility that we may become involved in intellectual property claims and litigation that could adversely affect the profitability of or our ability to sell our products, the possibility that our products may cause undesirable side effects and the fact that our ability to commercially distribute our products may be significantly harmed if the regulatory environment governing our products changes. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our Form 10-K for the year ended December 31, 2006. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Obagi Medical Products does not intend to update this information.